FibroGen Q1 loss $0.81; China roxadustat sales up 47%; pamrevlumab Ph3 data expected in 2023

KYNTRA BIO, INC.

2023-Q1 EPS reported -$0.81 revenue$36,161,000

Net loss $76.7M ($0.81/sh) vs $63.2M ($0.68/sh) in Q1 2022.
Total revenue $36.2M, down from $60.8M (prior year included $25M milestone).
China roxadustat net product revenue $24.2M (+28% YoY); total China sales $64.1M (+47%).
Completed non-dilutive term loan facility of up to $150M with Morgan Stanley Tactical Value.
Topline data from four Phase 3 trials (pamrevlumab in DMD, IPF, LAPC; roxadustat in CIA) expected through 3Q 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KYNTRA BIO, INC. reported financial results for the first quarter 2023.

Period: the first quarter 2023
Result: reported results

Exact text from the filing

On May 8, 2023, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended March 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-018795

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.